|
Market Closed -
Nasdaq
04:00:00 2026-08-21 pm EDT
|
5-day change | 1st Jan Change | ||
| 14.30 USD | -3.25% |
|
-7.74% | -8.80% |
Company Valuation: Monte Rosa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 949.7 | 368.3 | 282.8 | 426.4 | 1,021 | 1,220 | - | - |
| Change | - | -61.22% | -23.21% | 50.74% | 139.48% | 19.48% | - | - |
| Enterprise Value (EV) | 603.6 | 105.5 | 50.43 | 54.22 | 1,021 | 1,220 | 1,220 | 1,220 |
| Change | - | -82.52% | -52.19% | 7.5% | 1,783.24% | 19.48% | 0% | 0% |
| P/E | -6.9x | -3.31x | -2.15x | -7.08x | -34.1x | -8.8x | -7.54x | -8.59x |
| PBR | 2.75x | 1.32x | 1.58x | 1.91x | - | - | - | - |
| PEG | - | 0.1x | -0.1x | 0.1x | 0.6x | -0x | -0.5x | 0.7x |
| Capitalization / Revenue | - | - | - | 5.64x | 8.26x | 22.7x | 21.4x | 12x |
| EV / Revenue | - | - | - | 0x | 0x | 22.7x | 21.4x | 12x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -6.65x | -5.64x | -6.11x |
| EV / FCF | -0x | -0x | -0x | 0x | -0x | -14.5x | -17.4x | 39x |
| FCF Yield | -7.28% | -28.6% | -22.2% | 8.91% | -2.69% | -6.89% | -5.73% | 2.57% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.96 | -2.3 | -2.63 | -0.98 | -0.46 | -1.625 | -1.897 | -1.665 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 75.62 | 123.7 | 53.67 | 57.07 | 101.9 |
| EBITDA | -70.75 | -108.6 | -137.1 | -72.99 | - | - | - | - |
| EBIT 1 | -72.88 | -112.4 | -143.3 | -81.11 | -54.21 | -183.4 | -216.4 | -199.7 |
| Net income 1 | -73.96 | -108.5 | -135.4 | -72.7 | -38.63 | -164.2 | -201.3 | -188.5 |
| Net Debt | -346.1 | -262.8 | -232.4 | -372.1 | - | - | - | - |
| Reference price 2 | 20.42 | 7.61 | 5.65 | 6.94 | 15.68 | 14.30 | 14.30 | 14.30 |
| Nbr of stocks (in thousands) | 46,506 | 48,399 | 50,062 | 61,436 | 65,118 | 85,313 | - | - |
| Announcement Date | 3/29/22 | 3/16/23 | 3/14/24 | 3/20/25 | 3/17/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.8x | - | - | - | 1.22B | |
| 34.78x | 6.2x | 18.42x | 0.92% | 51.61B | |
| -21.47x | 297.59x | -22.09x | -.--% | 44.89B | |
| 33.46x | 3.25x | 14.02x | -.--% | 42.77B | |
| 49.05x | 5.7x | 31.17x | -.--% | 42.58B | |
| 29.21x | 8.45x | 21.35x | 0.39% | 31.82B | |
| 35.3x | 5.79x | 26.33x | -.--% | 17.33B | |
| 24.28x | 2.11x | 9.13x | 1.11% | 14.76B | |
| 78.97x | 4.14x | 16.07x | -.--% | 14.09B | |
| Average | 28.31x | 41.65x | 14.30x | 0.3% | 29.01B | |
| Weighted average by Cap. | 28.16x | 55.88x | 13.02x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GLUE Stock
- Valuation Monte Rosa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
